To deliver point-of-care diagnostics without the need for chemistry sets or finicky reagents, Atonarp has raised $50 million to continue building out its digital, laser-based molecular sensor platform.
The Tokyo-based company produces miniaturized and automated mass spectrometers and tools for optical spectroscopy, with plans for tests backed by artificial intelligence that could derive clinical results from very small patient samples.
It now offers hardware for real-time quality control in pharmaceutical production by scanning for contaminants as well as devices for use in semiconductor manufacturing.